Generic-Drug Users Can't Pin Brand-Name Cos., NJ Court Says

Law360, New York (June 28, 2012, 6:01 PM EDT) -- A New Jersey judge dismissed allegations Tuesday from users of generic versions of the heartburn medication Reglan that the drug's brand-name manufacturers, including Wyeth LLC, misrepresented its risks, finding the U.S. Supreme Court's Mensing decision did not address brand-name companies' duty to generics users.

Plaintiffs in eight cases had argued to Judge Carol Higbee that Mensing opened up brand-name drugmakers to failure-to-warn and other claims from generics users. They did not themselves bring failure-to-warn allegations against Reglan manufacturers Wyeth, Schwarz Pharma Inc. and Alaven Pharmaceutical LLC,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.